Enlivex Therapeutics Raises $212 Million in Private Placement
I'm PortAI, I can summarize articles.
Enlivex Therapeutics Ltd. announced a $212 million private placement through the sale of 212 million shares at $1.00 each, an 11.5% premium over the previous closing price. The funds will support a new digital asset treasury strategy and the development of Allocetra™ therapy for knee osteoarthritis. The transaction is expected to close by November 25, 2025, pending customary conditions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments